| human | Q5 |
| P227 | GND ID | 1118529502 |
| P10058 | IRIS UNIBO author ID | 00625 |
| P11718 | OPENBS author ID | 33990 |
| P496 | ORCID iD | 0000-0002-4508-0353 |
| P1053 | ResearcherID | A-3608-2016 |
| P214 | VIAF ID | 157147904930579090152 |
| P10832 | WorldCat Entities ID | E39PBJr7WBbr78JMQwwDWh8DMP |
| P108 | employer | University of Bologna | Q131262 |
| P735 | given name | Simona | Q12000546 |
| Simona | Q12000546 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q35683215 | 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia |
| Q33849578 | A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia |
| Q39259447 | A population-based study of chronic myeloid leukemia patients treated with imatinib in first line |
| Q38253243 | ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis |
| Q56999804 | ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o |
| Q54601012 | Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. |
| Q38057413 | Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop |
| Q38037648 | Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis |
| Q37027753 | Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias |
| Q46368483 | Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation |
| Q42145852 | Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. |
| Q36579071 | Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy |
| Q93541682 | Aurora kinase inhibitors: which role in the treatment of chronicmyelogenous leukemia patients resistant to imatinib? |
| Q37874391 | BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet |
| Q103826255 | BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS |
| Q41980844 | BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia |
| Q36542821 | BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships |
| Q35067505 | BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia |
| Q34308571 | Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model |
| Q36884361 | Best Practices in Chronic Myeloid Leukemia Monitoring and Management |
| Q54546042 | CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. |
| Q39961918 | Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. |
| Q44074873 | Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia |
| Q39516382 | Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? |
| Q52374501 | Chromothripsis in acute myeloid leukemia: biological features and impact on survival. |
| Q34642865 | Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q49888044 | Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. |
| Q36006408 | Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib |
| Q48240827 | Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. |
| Q33431360 | Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients |
| Q54595381 | Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. |
| Q46900229 | Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment |
| Q38562354 | Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients |
| Q56996659 | Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia |
| Q33728189 | Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy |
| Q42551545 | Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms |
| Q54775097 | Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. |
| Q54348230 | Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. |
| Q44858993 | Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib |
| Q43275641 | Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. |
| Q44847723 | Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia |
| Q56974816 | Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t |
| Q36265601 | Dual tyrosine kinase inhibitors in chronic myeloid leukemia. |
| Q85023798 | Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib |
| Q44680313 | Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia |
| Q37028628 | Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation |
| Q37026032 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. |
| Q38289019 | Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance |
| Q83851520 | F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib |
| Q48287068 | FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage |
| Q46919078 | First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy |
| Q44907835 | Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma |
| Q54327959 | Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutations. |
| Q58023817 | IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis |
| Q34358106 | IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia |
| Q27851487 | IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report |
| Q39826912 | Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute |
| Q56992002 | Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method |
| Q45023456 | Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia |
| Q37183434 | Imatinib mesylate for the treatment of chronic myeloid leukemia |
| Q50086212 | Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. |
| Q56996402 | Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party |
| Q37163834 | Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase |
| Q38153173 | Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia |
| Q36093137 | In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants |
| Q47113340 | Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia |
| Q41768439 | Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini |
| Q38929965 | Interferon in CML: back to the past, or towards the future? |
| Q45958805 | Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. |
| Q46192367 | Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy |
| Q58449026 | Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era |
| Q36708942 | Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia |
| Q40821920 | Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. |
| Q46828221 | Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. |
| Q54574009 | Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. |
| Q38176284 | Molecular monitoring |
| Q38214274 | Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor |
| Q33948671 | Molecular response in CML: where is the bar? |
| Q44673850 | Molecular response to imatinib in late chronic-phase chronic myeloid leukemia |
| Q34353508 | Molecular therapy for multiple myeloma. |
| Q51921082 | Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. |
| Q35849776 | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results |
| Q36599984 | Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management |
| Q38571435 | Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia |
| Q37810095 | New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia |
| Q37644029 | New targets for Ph+ leukaemia therapy |
| Q36093870 | New tyrosine kinase inhibitors in chronic myeloid leukemia. |
| Q43406815 | Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase |
| Q91695449 | Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper |
| Q90183997 | Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper |
| Q40996735 | Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients |
| Q104751224 | Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia |
| Q38389475 | Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients |
| Q56962608 | Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia |
| Q43262982 | Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia |
| Q46127676 | Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. |
| Q37586848 | Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance |
| Q28678649 | Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis |
| Q57005466 | Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one |
| Q37470939 | Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure |
| Q34750545 | Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis |
| Q45933610 | Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. |
| Q41613498 | Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case |
| Q79370343 | Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia |
| Q38762631 | Present and future of molecular monitoring in chronic myeloid leukaemia |
| Q92252507 | Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study |
| Q39642161 | Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia |
| Q44590753 | Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. |
| Q34644820 | Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia |
| Q57008082 | Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia |
| Q56995709 | Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain |
| Q37644004 | Response definitions and European Leukemianet Management recommendations |
| Q46124555 | Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party |
| Q39924810 | Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia |
| Q56995760 | Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL |
| Q46155376 | Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? |
| Q42131722 | Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant). |
| Q80292400 | Targeted therapy and the T315I mutation in Philadelphia-positive leukemias |
| Q40217698 | The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib |
| Q37212678 | The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis |
| Q34166538 | The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party |
| Q41264328 | The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report |
| Q56994592 | The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study |
| Q54177638 | The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis. |
| Q64097232 | Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges |
| Q46136039 | Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response |
| Q45924192 | Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. |
| Q42811718 | Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain |
| Q40177674 | Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response |
| Q33284886 | WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. |
| Q47694495 | What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer? |
| Q41816292 | c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration |
| Q50193901 | c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. |
Search more.